Report Overview

The global microbiome therapeutics market size was valued at USD $1.31 Billion in 2019 and is expected to grow to $XX billion at a CAGR of xx% through 2028.

Increasing prevalence of diseases due to dysbiosis of microbiota in the gut and provisioning of a high amount of funding for biological drug development studies are the key drivers affirming growth of this market.

Gut microbiome has been known to be associated with the good health of a person. Researchers have reported that alteration in a number of microorganisms such as firmicute, Bacteroidetes, and actinobacteria leads to the development of gastrointestinal disorders, diabetes, arthritis, and other neurological disorders. Heavy and long-term use of antibiotics, unhealthy lifestyle, and increasing age are some of the factors reducing the number of beneficial microorganisms in the human body.

Low level of beneficial microbiota helps the growth of fatal infectious diseases and organisms, such as Clostridium difficile (C. difficile) and ulcerative colitis. C. difficile has been reported to affect over half a million people in a single year and has a high recurrence rate. People on antibiotic treatment are 7 to 10 times more likely to get affected by C. difficile infection during the treatment and the months following it.

Increasing collaboration between pharmaceutical companies for development of novel drugs is also a high impact rendering factor for growth. For instance, Seres Therapeutics, U.S., and Nestl Health Science have entered into a collaborative agreement for development and commercialization of extensive product pipeline for ulcerative colitis and C. difficile infection.



Market Drivers

The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, growing prevalence of chronic diseases is anticipated to boost the growth of the market as well. The human microbiome therapeutics market analysis includes application segment and geographic landscapes.